Cookies?
Library Header Image
LSE Research Online LSE Library Services

HTA programme response to the challenges of dealing with orphan medicinal products: process evaluation in selected European countries

Nicod, Elena, Annemans, Lieven, Bucsics, Anna, Lee, Anne, Upadhyaya, Sheela and Facey, Karen (2017) HTA programme response to the challenges of dealing with orphan medicinal products: process evaluation in selected European countries. Health Policy. ISSN 0168-8510

[img]
Preview
PDF - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (929kB) | Preview
Identification Number: 10.1016/j.healthpol.2017.03.009

Abstract

Background Challenges commonly encountered in HTA of orphan medicinal products (OMPs) were identified in Advance-HTA. Since then, new initiatives have been developed to specifically address issues related to HTA of OMPs. Objective and methods This study aimed to understand why these new HTA initiatives in England, Scotland and at European-level were established and whether they resolve the challenges of OMPs. The work of Advance-HTA was updated with a literature review and a conceptual framework of clinical, regulatory and economic challenges for OMPs was developed. The new HTA programmes were critiqued against the conceptual framework and outstanding challenges identified. Results The new programmes in England and Scotland recognise the challenges identified in demonstrating the value of ultra-OMPs (and OMPs) and that they require a different process to standard HTA approaches. Wider considerations of disease and treatment experiences from a multi-stakeholder standpoint are needed, combined with other measures to deal with uncertainty (e.g. managed entry agreements). While approaches to assessing this new view of value of OMPs, extending beyond cost/QALY frameworks, differ, their criteria are similar. These are complemented by a European initiative that fosters multi-stakeholder dialogue and consensus about value determinants throughout the life-cycle of an OMP. Conclusion New HTA programmes specific to OMPs have been developed but questions remain about whether they sufficiently capture value and manage uncertainty in clinical practice.

Item Type: Article
Official URL: http://www.sciencedirect.com/science/journal/01688...
Additional Information: © 2017 The Authors © CC BY-NC-ND 4.0
Divisions: Social Policy
LSE Health
Subjects: R Medicine > RA Public aspects of medicine
R Medicine > RS Pharmacy and materia medica
Sets: Departments > Social Policy
Research centres and groups > LSE Health
Date Deposited: 03 Apr 2017 09:05
Last Modified: 20 Nov 2019 12:03
URI: http://eprints.lse.ac.uk/id/eprint/72004

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics